Group 1 - The core point of the article is that Shengxiang Bio plans to establish a new investment fund with a target size of 1 billion RMB, focusing on AI medical applications and innovative medical technologies [1] - Shengxiang Bio's stock closed at 21.75 RMB, with a market capitalization of 12.602 billion RMB, reflecting a slight increase of 0.09% from the previous trading day [1] - The company will contribute 370 million RMB to the fund, representing a 37% stake, which aims to enhance its strategic layout in the medical field [1] Group 2 - The fund will primarily invest in companies with leading technologies and significant market potential in the medical industry [1] - The investment decision has been approved by the board of directors and will not be included in the company's consolidated financial statements [1] - The funding will be sourced from the company's own or self-raised capital, ensuring no significant adverse impact on its operations [1]